KR20140140902A - Composition for reducing alcoholic hangup and inhibiting liver injury containing Hippophae rhamnoides extract - Google Patents
Composition for reducing alcoholic hangup and inhibiting liver injury containing Hippophae rhamnoides extract Download PDFInfo
- Publication number
- KR20140140902A KR20140140902A KR1020130061908A KR20130061908A KR20140140902A KR 20140140902 A KR20140140902 A KR 20140140902A KR 1020130061908 A KR1020130061908 A KR 1020130061908A KR 20130061908 A KR20130061908 A KR 20130061908A KR 20140140902 A KR20140140902 A KR 20140140902A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- alcohol
- pharmaceutical composition
- present
- activity
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 240000000950 Hippophae rhamnoides Species 0.000 title claims abstract description 16
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 16
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 16
- 231100000753 hepatic injury Toxicity 0.000 title claims description 7
- 230000002401 inhibitory effect Effects 0.000 title description 5
- 230000001476 alcoholic effect Effects 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 100
- 206010019133 Hangover Diseases 0.000 claims abstract description 22
- 230000004060 metabolic process Effects 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 235000013399 edible fruits Nutrition 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 241001125048 Sardina Species 0.000 claims description 9
- 235000019512 sardine Nutrition 0.000 claims description 9
- 241000331162 Echinosophora koreensis Species 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 241000192043 Echinochloa Species 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 244000166124 Eucalyptus globulus Species 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical group CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 24
- 231100000234 hepatic damage Toxicity 0.000 abstract description 9
- 230000008818 liver damage Effects 0.000 abstract description 9
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 17
- 235000013305 food Nutrition 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 15
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 15
- 241000208838 Asteraceae Species 0.000 description 14
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 13
- 239000000654 additive Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229950006238 nadide Drugs 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000002023 wood Substances 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 229960001031 glucose Drugs 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 235000003935 Hippophae Nutrition 0.000 description 4
- 241000229143 Hippophae Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940077731 carbohydrate nutrients Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940033134 talc Drugs 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000003056 antler Anatomy 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 229940071117 starch glycolate Drugs 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 244000058871 Echinochloa crus-galli Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000011999 Panicum crusgalli Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Abstract
Description
The present invention relates to the use of the extract of Echinochloa crus-galli as a pharmaceutical composition for suppressing or damaging liver damage.
Alcohol is known to stimulate the central nervous system of the brain, which inhibits consciousness and movement, and has sleep and anesthetic effects. Along with the economic growth in recent years, many foods using alcohol have been developed, and they are becoming a favorite food for the stressed modern people. Alcohol in the body is oxidatively metabolized in the liver by alcohol dehydrogenase (ADH) to produce acetaldehyde. The resulting metabolite, acetaldehyde, is oxidized to acetic acid by acetaldehyde dehydrogenase (ALDH) and some excreted as urine or CO 2 . Alcohol is known to have various effects on the liver metabolism depending on the intake. Acetaldehyde, which is an intermediate product produced in the oxidation process rather than the alcohol itself, causes damage to the hepatocytes and causes various diseases. Most hangover products developed so far have been focused on promoting the activity of alcoholase (ADH), but the hangover symptoms that are actually felt after drinking are known to be due to acetaldehyde.
The genus Hippophae rhamnoides L. is a tree plant, characterized by a brownish thorn, and the fruit is orange-yellow. Native fruit has condensed important nutrients such as rich vitamins and trace elements, natural minerals, amino acids and essential fatty acids. However, there are not enough studies on the genus Epidermidis. Therefore, there is a lack of information on the nutritional value and physiological activity of Epimedium.
Therefore, the inventors of the present invention confirmed that the extract of Sadakki nodule had a liver protective effect while investigating the physiological activity of sardine fruit, and confirmed that it accelerated the activity of acetaldehyde decomposing enzyme (ALDH) It is expected to be useful as a composition for relieving hangover.
It is an object of the present invention to provide a pharmacological composition for suppressing liver injury or hangover which contains extract of Hippophae rhamnoides L. as an active ingredient.
It is still another object of the present invention to provide a method for producing the above pharmaceutical composition for inhibiting or preventing hangover.
In addition, another object of the present invention is to provide a food composition for preventing hangover and protecting the liver containing an extract of Hippophae rhamnoides L. as an active ingredient.
In order to achieve the above object, the present invention provides a pharmaceutical composition for suppressing liver injury or hanging sputum containing a fruit extract of Hippophae rhamnoides L. as an active ingredient.
In order to achieve the above object, the present invention also provides a method for producing the pharmaceutical composition for suppressing liver injury or hangover.
In order to achieve the above object, the present invention provides a food composition for the treatment of hangover and liver protection, which comprises extract of Hippophae rhamnoides L. fruit as an active ingredient.
The present antler wood ( Hippophae rhamnoides L.) fruit extract has a protective effect against liver damage and promotes the activity of acetaldehyde decomposing enzyme (ALDH). Therefore, it is expected that it can be usefully used as a composition for inhibiting liver damage and removing hangover.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic diagram showing a process for producing an extract of Saccharomyces cerevisiae according to the present invention. FIG.
FIG. 2 is a graph showing changes in the activities of alcohol digestive enzymes (ADH) and acetaldehyde degrading enzymes (ALDH) by the extracts of Saccharomyces cerevisiae according to the present invention.
FIG. 3 is a graph showing changes in antioxidant enzyme (SOD) activity by the extract of Echinochloa crus-galliensis according to the present invention;
NC: control group in which 1 x PBS was administered instead of alcohol;
EC: Negative control with 1 x PBS administered before alcohol administration; And
AC: Experimental group treated with Echinoderm extract before alcohol administration.
Hereinafter, the present invention will be described in detail.
As used herein, the term " inhibition of liver injury "means any action by which administration of the pharmaceutical composition of the present invention prevents or protects against liver damage.
As used herein, the term "hangover resolution" means any action in which hangover caused by acetaldehyde caused by alcohol metabolism after alcohol ingestion is reduced or changed by administration of the composition of the present invention.
The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.
The term " pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit or risk rate applicable to medical treatment, including the type of disease, severity, activity of the drug, The time of administration, the route and rate of excretion of the drug, the duration of the treatment, factors including drugs used simultaneously and other factors well known in the medical arts.
The subject is a vertebrate animal, preferably a mammal, more preferably an experimental animal such as a mouse, a rabbit, a guinea pig, a hamster, a dog or a cat, and most preferably an ape-like animal such as a chimpanzee or a gorilla.
Alcohol is absorbed in the gastrointestinal tract after drinking, and is distributed in the body tissues including the brain and the tube through the bloodstream. Alcohol transported through the bloodstream is oxidized by alcohol dehydrogenase (ADH) to acetaldehyde. Acetaldehyde is oxidized to acetic acid by aldehyde dehydrogenase (ALDH). ADH and ALDH use a coenzyme called NAD, which produces NADH and H + . Alcohol that has been converted to acetic acid is then transported to each tissue and then oxidized (metabolized) to acetyl-CoA to convert to carbon dioxide and water.
AST, which is widely used as an index of liver function, is an enzyme present in the liver, heart, muscle, and kidney. When the tissue is damaged, the enzyme is released into the blood and the enzyme activity is increased. , And liver cirrhosis. ALT is also an enzyme present in the liver, and its activity is increased by hepatitis, liver necrosis, and liver cirrhosis.
The present invention relates to an antimicrobial agent rhamnoides L.) fruit extract as an active ingredient.
Preferably, the extract is extracted using water, a C 1 to C 2 lower alcohol or a mixture thereof, and the lower alcohol is preferably ethanol or methanol, but is not limited thereto.
The pharmaceutical composition preferably protects hepatocytes by promoting the activity of antioxidant enzymes, but is not limited thereto.
The pharmaceutical composition preferably decomposes acetaldehyde, which is a hangover inducing substance produced by alcohol metabolism by promoting the activity of ALDH, but is not limited thereto.
The pharmaceutical composition preferably inhibits liver damage caused by alcohol to reduce the amount of alanine aminotransferase (ALT) or aspartate aminortansferase (AST) in the blood, but is not limited thereto.
The pharmaceutical composition preferably reduces blood alcohol concentration, but is not limited thereto.
The pharmaceutical composition of the present invention may further contain one or more active ingredients showing the same or similar functions. The pharmaceutical composition of the present invention contains 0.0001 to 10% by weight, preferably 0.001 to 1% by weight of the protein, based on the total weight of the pharmaceutical composition. In addition, the pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
The pharmaceutical composition of the present invention may be formulated into a unit dosage form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents. Further, quadrupole tree according to the invention (Hippophae The pharmaceutical composition containing the rhamnoides L.) fruit extract may be in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions , preferably suspensions, freeze-dried preparations, non-aqueous injections, or in the form of an aqueous injection solution, and more preferably, may be used in formulating a sterile injectable solution formulation, drama tree (Hippophae lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate which may be contained in pharmaceutical compositions containing rhamnoides L. , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it can be prepared by using a solvent, a dissolution aid, a buffer, an isotonic agent, a stabilizer, an antioxidant, an anhydrous agent, a suspending agent and the like commonly used in the art. As the solvent, the additive and the diluent, , Physiological saline, pH adjusting agent, albumin, sodium chloride, mannitol, injection of Ringer's gel, glucose and the like. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
The pharmaceutical composition of the present invention may be administered orally, subcutaneously, subcutaneously or topically through the skin (transdermal administration), orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) Oral, rectal or intravenous, intramuscular, intradermal, subcutaneous, intra-uterine or intracerebroventricular injections. The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease. The oral dosage of the pharmaceutical composition of the present invention is preferably 0.001 to 100 mg / kg (body weight) per day, more preferably 0.01 to 10 mg / kg (body weight), but is not limited thereto. However, for the most favorable effect, the antler wood of the present invention ( Hippophae rhamnoides L.) fruit extract is administered at a dose of from 8 micrograms to 5 milligrams per day, preferably from 8 micrograms to 2 milligrams, more preferably from 16 micrograms to 1 milligram per day, Lt; RTI ID = 0.0 > intramuscularly. ≪ / RTI > The administration frequency can be administered once a day, several times a day, once a day for two days to one week, etc., but there is no limit to the number of times of administration. The dose, administration frequency and administration method are not intended to limit the scope of the present invention in any aspect.
The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate Starch glycolate, starch glycolate, starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, sodium carboxymethylcellulose, sodium carboxymethylcellulose, sodium carboxymethylcellulose, Calcium stearate, white sugar, dextrose, sorbitol and talc may be used. The pharmaceutically acceptable additives according to the present invention are preferably included in the pharmaceutical composition in an amount of 0.1 to 90 parts by weight, but are not limited thereto.
On the other hand, the pharmaceutical composition according to the present invention is extracted from plants, so that it can be safely used for prolonged use for preventive purposes without serious toxicity and side effects.
In addition,
1) dissolving sardine seeds in a solvent to prepare an extract of sardine seeds;
2) concentrating the seed extract of the above 1); And
And 3) filtering the concentrated extract of Echinochloa cruskwood of step 2).
The solvent of step 1) is preferably water, a C 1 to C 2 lower alcohol or a mixture thereof, more preferably the lower alcohol is ethanol or methanol, and the ethanol is most preferably 50 to 90% ethanol But is not limited thereto.
In addition,
1) dissolving sardine seeds in a solvent to prepare an extract of sardine seeds;
2) concentrating the seed extract of the above 1);
3) filtering the concentrated sardine fruit extract of step 2); And
4) lyophilizing the filtered seed extract of step (3) and correcting the pH. The present invention also provides a method for preparing a pharmaceutical composition for suppressing liver damage or hangover.
In addition, the present invention provides a food composition for the treatment of hangover and liver protection comprising extract of Hippophae rhamnoides L. as an active ingredient.
The present antler wood ( Hippophae The concentration of the rhamnoides L.) fruit extract is preferably 0.01 to 100 [mu] M, but is not limited thereto.
The health functional food may be powder, granule, tablet, capsule or beverage, but is not limited thereto.
The food of the present invention can be used as a food product of the present invention ( Hippophae rhamnoides L.) fruit extract can be added directly or together with other food or food ingredients, and can be suitably used according to conventional methods.
There is no particular limitation on the kind of the food. Examples of foods to which the Hippophae rhamnoides L. fruit extract of the present invention can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, Products, soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and includes foods in the conventional sense.
The beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates are sugar alcohols such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.
The quadrupole tree as essential components, which may include in the food composition of the present invention (Hippophae rhamnoides L.) There are no particular restrictions on other components other than the fruit extract, and it may contain various herbal medicine extracts, food-aid additives or natural carbohydrates as an additional ingredient like ordinary foods. In addition, the food-aid additive may further include food-aid additives. Examples of the food-aid additive include food-aid additives customary in the art, for example, flavoring agents, flavoring agents, coloring agents, fillers, stabilizers and the like. Examples of such natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above . In addition to the above, the food composition of the present invention may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, etc. Besides natural fruit juices and fruit juice drinks and vegetable drinks These additives may be used independently or in combination. Although the ratio of such additives is not critical, 100 parts by weight of the composition of the present invention It is generally selected from the range of 0.01 to 0.1 wt.
In a specific embodiment of the present invention, the present inventors have prepared an extract of Sambrook tree, and confirmed that the extract of Sambrook tree extract promotes ALDH activity more than ADH. In addition, in the alcohol - treated mice, it was confirmed that the extract of Echinosophora koreensis was anatomically safe by lowering the ratio of the liver weight to the total weight increased by alcohol. In addition, it was confirmed that the extract of Echinosophora koreensis decreased the blood alcohol concentration and decreased the activity of AST and ALT increased by alcohol. In addition, it was confirmed that the activity of SOD enzyme having protective activity against oxidative stress induced by alcohol was enhanced by the extract of Sadakiri nodule, and thus it has a protective effect against alcohol damage by liver.
Thus, it was found that the extract of Echinosophora koreensis of the present invention inhibits liver damage caused by alcohol, and accelerates the decomposition of acetaldehyde, which is a hangover inducing substance, generated in alcohol metabolism.
Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples in order to facilitate understanding of the present invention. It should be understood, however, that the following examples and experimental examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The embodiments and experimental examples of the present invention are provided to enable those skilled in the art to more fully understand the present invention.
< Example 1> Antique wood Production of fruit extract
Hippophae 50 g of rhamnoides L.) fruit (www.vitamintree.biz) was dissolved in 500 ml of 70% (v / v) ethanol and extracted at 80 ° C for 3 hours. The extract was concentrated under reduced pressure at 40 占 폚, and the concentrated extract was filtered and lyophilized for 3 days to prepare a powder. The prepared powder was finally dissolved in 1X phosphate buffered saline (PBS), the pH value was adjusted to 7 to 7.5 and stored at -20 ° C (FIG. 1).
< Experimental Example 1> Antique wood Effect of Fruit Extract on Alcohololytic Enzyme Activity
The activity of alcohol degrading enzyme (ADH) and acetaldehyde decomposing enzyme (ALDH) was measured in order to confirm the hangover resolution effect of the extract of Sadduceus syrup obtained in Example 1 above.
Specifically, 0.1 ml of alcohol, 0.5 ml of NAD aqueous solution (2 mg / ml), 0.1 ml of sardine fruit extract and 1.1 ml of 0.01 M glycine NaOH (pH 8.8) were mixed and reacted in a constant temperature water bath at 25 ° C for 10 minutes The concentration of NADH (nicotinamide adenine dinucleotide) produced by the reaction of the coenzyme NAD used in the alcohol metabolism of the ADH was measured with a spectrophotometer (Multiskan) using ADH (10 unints / ml) GO UV / Vis microplate spectrophotometer, Thermo Scientific). In addition, 0.1 ml of distilled water, 0.3 ml of 1 M Tris HCl, 0.1 ml of 3M KCl, 0.1 ml of Nuclear Fruit Extract, 0.1 ml of 20 mM NAD, 0.1 ml of 0.33 M 2-mercaptoethanol and 0.1 ml of 0.1 M acetaldehyde were mixed, (1 unit / ml) was added to the reaction solution and the concentration of nicotinamide adenine dinucleotide (NADH) produced by the reaction of the coenzyme NAD was measured with a spectrophotometer (Multiskan GO UV / Vis microplate spectrophotometer, Thermo Scientific). In addition, the activity of ADH and ALDH was expressed by the ratio of the absorbance at the end of the reaction to the absorbance of the control, and was calculated based on the following equation.
(A: absorbance of control (distilled water), B: absorbance of experimental group)
As a result, the activity of acetaldehyde decomposing enzyme (ALDH) which decomposes acetaldehyde, which is a cause of hangover, was not significantly increased while the activity of alcohololytic enzyme (ADH) (Fig. 2). This study confirmed that the extract of Echinosophora koreensis effectively activates ALDH and promotes the decomposition of acetaldehyde, which is a cause of hangover.
< Experimental Example 2> in the animal model Antique wood Identification of the effect of fruit extract
<2-1> Antique wood Identification of ethanol degradation ability of fruit extract
In order to confirm the ethanol degradation effect of the extracts of Bombyx mori L., blood alcohol levels of alcohol - treated ICR mice were measured.
Specifically, four 25- to 30-g ICR mice were used as the experimental animals, and they were used for the post-breeding experiment for 2 weeks. Alcohol administration in mice was performed by oral administration of 25% alcohol at 1 g / kg body weight once, and NC group received 1 × PBS only without alcohol. In the alcohol-treated group, the control group (EC) and the seed extract of Asteraceae (AE) were divided into groups. In the AE group, mice were orally administered with 100 mg / ml of Echinacea fruit extract at a dose of 1 ml / kg for 5 days 30 minutes before the alcohol administration , And 1XPBS was orally administered to the EC group at 1 ml / kg for 30 minutes before the administration of alcohol, Thereafter, blood was collected from the NC, EC, and AE groups through orbital blood collection. The collected blood was centrifuged at 4,800 rpm for 30 minutes, and then the supernatant was separated and the concentration of ethanol was measured therefrom.
As a result, the AE group pretreated with the extract of Echinosophora koreensis decreased the blood alcohol level by 0 compared with the EC-treated group (Table 1).
Therefore, although the activity of ADH was not increased, the concentration of ethanol in the blood was decreased as in Experimental Example 1, and the effect of the extract was higher than that of ADH .
NC: 1X PBS administration (Normal control group)
EC: 1X PBS before alcohol administration
AE: Dextrose extract before alcohol administration
<2-2> Liver weight measurement in alcohol-fed animals
As in Experiment Example <2-1>, after the administration of alcohol or Sodomai fruit extract to each mouse group, the weight change of the NC group, the EC group and the AE group was measured and the weight of the main organs responsible for the metabolism of alcohol was measured And the ratio of the liver weight to the total weight is shown in Table 2 below.
As a result, the ratio of liver weight to total weight, which was increased due to alcohol administration, was decreased similarly to the control group at the time of treatment with Saddust extract.
Therefore, it is considered that the extract of Echinosophora koreensis decreased the risk of increase by alcohol.
(n = 4)
NC: 1X PBS administration (Normal control group)
EC: 1X PBS before alcohol administration
AE: Dextrose extract before alcohol administration
<2-3> Antique wood Identification of the liver damage inhibitory effect of fruit extract
To investigate the effects of the extracts of Echinochloa crus-galli extract on liver function, serum ALT activity and alanine aminotransferase activity (ALT activity assay kit (Biovision) and AST activity assay kit (Biovision).
As a result, it was confirmed that the activity of AST and ALT in the EC group was increased as compared with that of the NC group (Table 3). Thus, it was found that the extract of Echinosophora koreensis was effective in alleviating the damaged liver function by alcohol treatment and thus also protecting the liver.
NC: 1X PBS administration (Normal control group)
EC: 1X PBS before alcohol administration
AE: Dextran extract before alcohol administration
<2-4> Antique wood Identification of Antioxidant Enzyme Activity by Fruit Extract
The activity of SOD (superoxide dismutase) enzyme acting on hepatocytes was measured in order to examine the effect of ethanol extract induced spermatogonium fruit extract prepared in Example 1 on oxidative stress.
Specifically, the liver of the NC group, the EC group and the AE group ICR mouse of Experimental Example <2-1> was individually extracted and homogenized, followed by centrifugation at 12,000 g for 10 minutes. SOD activity assay kit (Cell Biolabs, Inc) was used to determine the activity of the enzyme using the supernatant separated by centrifugation.
As a result, SOD activity was higher in ethanol - treated EC group than in NC group. In order to overcome oxidative stress caused by alcohol, SOD activity was activated, and AE group pretreated with sodurian fruit extract before alcohol administration had SOD activity EC group (Fig. 3).
Therefore, it was found that the extract of Sadakki extract promotes the activity of the antioxidant enzyme, thereby effectively protecting the hepatocyte from the oxidative stress caused by the alcohol.
Based on the results of the above-described Examples and Experimental Examples, various preparation examples and preparation examples will be presented below. However, it should be apparent to those skilled in the art that these preparation examples and preparation examples are for illustrating the present invention and that the preparation of the present invention is not limited to these preparation examples and preparation examples.
< Formulation example 1> Preparation of tablets
1 mg of the seed extract of the present invention
Corn starch 68 mg
Lactose 90 mg
40 mg of microcrystalline cellulose
Magnesium stearate 2 mg
According to the conventional preparation method of tablets, the above ingredients were added in the prescribed amounts, uniformly mixed, stirred, and then granulated. After drying, the tablets were used to produce the desired tablets containing 1 mg of the extract of Echinochloa crus-galliensis according to the present invention as active ingredients per one tablet.
< Formulation example 2> Preparation of capsule
1 mg of the seed extract of the present invention
Corn starch 68 mg
Lactose 90 mg
40 mg of microcrystalline cellulose
Magnesium stearate 2 mg
According to a conventional method for preparing a capsule, the above components were added in the prescribed amounts and uniformly mixed. Then, the mixture was filled in gelatin capsules of appropriate size so as to contain 1 mg of the extract of Euglenia cinerea of the present invention per capsule, .
< Formulation example 3> Sanje Produce
1 mg of the seed extract of the present invention
Lactose 100 mg
Talc 10 mg
Maintenance 5 mg
According to a conventional method for producing an acid, the above ingredients are mixed and filled in an airtight container to prepare a powder.
< Formulation example 4> Liquid Produce
1 mg of the seed extract of the present invention
10 g per isomer
5 g mannitol
Vitamin C 50 mg
Serine 50 mg
Maintenance amount
Purified water balance
According to a conventional method for producing a liquid agent, the above components are mixed to prepare a liquid agent.
< Manufacturing example 1> Manufacturing of food
<1-1> Manufacture of flour food
To 100 parts by weight of wheat flour were added 0.5 to 5.0 parts by weight of the extract of Saccharomyces cerevisiae of the present invention to wheat flour, and bread, cake, cookies, crackers and noodles were prepared using this mixture.
<1-2> soup And juicy ( gravies )
Soup and juice were added to soup and juice to 100 parts by weight of soup and juice, and 0.1 to 5.0 parts by weight of the extract of the present invention were added to soup and juice.
<1-3> Ground Beef Produce
Ground beef for health promotion was prepared by adding 10 parts by weight of the extract of Saccharomyces cerevisiae of the present invention to ground beef to 100 parts by weight of ground beef.
<1-4> Dairy products ( dairy products )
5 to 10 parts by weight of the extract of the present invention were added to milk to 100 parts by weight of milk and various dairy products such as butter and ice cream were prepared using the milk.
<1-5> Solar Produce
Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
The seed powder extract of the present invention was prepared.
The above-prepared cereals, seeds and the seed extract of the present invention were blended in the following proportions.
(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
(3 parts by weight) of the present invention,
(0.5 part by weight),
(0.5 parts by weight)
< Manufacturing example 2> Manufacturing of beverages
<2-1> Health drink Produce
(5 g) of the present invention was homogeneously blended with liquid ingredients such as fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5% And packaged in small containers such as glass bottles and plastic bottles.
<2-2> Preparation of vegetable juice
Vegetable juice was prepared by adding 5 g of the seed extract of the present invention to 1,000 ml of tomato or carrot juice.
<2-3> Preparation of fruit juice
The fruit juice was prepared by adding 1 g of the seed extract of the present invention to 1,000 ml of apple or grape juice.
Claims (10)
2) concentrating the seed extract of the above 1); And
And 3) filtering the concentrated extract of Echinosophora koreensis in step 2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130061908A KR20140140902A (en) | 2013-05-30 | 2013-05-30 | Composition for reducing alcoholic hangup and inhibiting liver injury containing Hippophae rhamnoides extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130061908A KR20140140902A (en) | 2013-05-30 | 2013-05-30 | Composition for reducing alcoholic hangup and inhibiting liver injury containing Hippophae rhamnoides extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140140902A true KR20140140902A (en) | 2014-12-10 |
Family
ID=52458552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130061908A KR20140140902A (en) | 2013-05-30 | 2013-05-30 | Composition for reducing alcoholic hangup and inhibiting liver injury containing Hippophae rhamnoides extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20140140902A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101710303B1 (en) | 2016-05-04 | 2017-02-24 | 재단법인 전남생물산업진흥원 | Pharmaceutical composition containing elaeagnus umbellata thunberg extract for immune-enhancing |
-
2013
- 2013-05-30 KR KR1020130061908A patent/KR20140140902A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101710303B1 (en) | 2016-05-04 | 2017-02-24 | 재단법인 전남생물산업진흥원 | Pharmaceutical composition containing elaeagnus umbellata thunberg extract for immune-enhancing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101974442B1 (en) | Agent for improvement of catechin bioavailability comprising cyclodextrin | |
| KR101613693B1 (en) | Composition for Prevention or Treatment of Skin Disease Comprising an Extract of Sargassum Horneri and Method of Preparing The Same | |
| KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
| KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| KR20160140417A (en) | Composition for Liver Function Improvement Comprising Natural Extracts | |
| KR20140140902A (en) | Composition for reducing alcoholic hangup and inhibiting liver injury containing Hippophae rhamnoides extract | |
| KR20220132349A (en) | Composition for preventing, ameliorating or treating metabolic disease comprising leaf extract of new pepper cultivar as effective component | |
| KR102151003B1 (en) | Composition for eliminating hangover comprising fermented liquor of aged sprout ginseng extract as effective component | |
| KR20180086935A (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
| KR102080204B1 (en) | Clathrate compound of Schisandra chinensis extract and method for its production | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
| KR102527154B1 (en) | Pharmaceutical composition for preventing or treating constipation with enhanced packaging stability comprising fermentation of Prunus domestica and Ficus carica as an active ingredient | |
| KR101624293B1 (en) | Composition for enhancing immune response comprising extract of Benincasa hispida Cogniaux or fermented extract of the same | |
| KR101991746B1 (en) | Agent for improvement of cathechin bioavailability | |
| KR102656187B1 (en) | Pharmaceutical composition for preventing or treating tuberculosis disease comprising Agastache rugosa extract as effective component | |
| KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
| KR20190084732A (en) | A composition for improving, preventing and treating obesity comprising fermented pollack skin | |
| KR101886802B1 (en) | Agent for improvement of cathechin bioavailability | |
| EP3960189A1 (en) | Antiviral composition having antiviral activity against coronavirus and variant viruses thereof | |
| KR20150031372A (en) | Phamaceutical and food composition for preventing or treating diabetes comprising extract of fruit from Hoppophea rhamnoids as effective component | |
| KR101899086B1 (en) | Composition for preventing, improving or treating liver damage | |
| KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
| KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
| KR20160143041A (en) | A composition for prevention and treatment of infectious diseases comprising Allium hookeri as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E601 | Decision to refuse application |